Fiscal Year 2011 Tuberous Sclerosis Complex Research Program (TSCRP)
Reference Table of Award Mechanisms and Submission Requirements

| Award Mechanism          | Eligibility                                                                 | Key Mechanism Elements                                                                 | Funding                                                                 | Submission Deadline |
|--------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------|                                                                      |                     |
| Career Transition Award  | Must be a postdoctoral investigator with at least 2 years of postdoctoral experience by the time of application submission. | • Supports TSC researchers during the transition from postdoctoral training to an independent position.  
• Funds the final 2 years of the postdoctoral position and the first 2 years of a faculty/independent position.  
• Preliminary data required. | • The maximum period of performance is 4 years.  
• The maximum allowable funding for the entire period of performance is $338,000 in direct costs.  
  o The maximum allowable funding is $69,000 per year in direct costs for each postdoctoral year (years 1-2).  
  o The maximum allowable funding is $100,000 per year in direct costs for each faculty-level position year (years 3-4).  
• Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 18, 2011  
5:00 p.m. Eastern time (ET)  
Application:  
August 1, 2011  
11:59 p.m. ET |
| Clinical Trial Award     | Must be an independent investigator at or above the level of Assistant Professor (or equivalent). | • Fund Phase 0, I, or II clinical trials relevant to TSC. Combinations of phases are permitted.  
• Preclinical data required.  
• Phase I or pilot clinical trial data required for Phase II clinical trial applications. | • The maximum period of performance is 4 years.  
• The maximum allowable funding for the entire period of performance is $1,000,000 in direct costs.  
• Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. | Pre-application (LOI*):  
July 21, 2011  
5:00 p.m. Eastern time (ET)  
Application:  
August 4, 2011  
11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Exploration – Hypothesis Development Award**   | Independent investigators (including junior faculty but excluding postdoctoral fellows).        | - Fund the initial exploration of innovative, untested research and pursue serendipitous observations.  
- Preliminary data is encouraged but not required.  
- Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. | - The maximum period of performance is 2 years.  
- The maximum allowable funding for the entire period of performance is $100,000 in direct costs.  
- Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 18, 2011  
5:00 p.m. Eastern time (ET)  
Application:  
August 1, 2011  
11:59 p.m. ET |
| **Idea Development Award**                       | **Principal Investigator:** Must be an independent investigator at or above the level of Assistant Professor (or equivalent).  
**Optional Qualified Collaborator:** Must be at or above the level of Assistant Professor (or equivalent). | - Encourage high-impact, innovative research that will drive the field of TSC research forward.  
- Preliminary data required.  
- Optional Qualified Collaborator: Collaborations that meet the criteria outlined in the Program Announcement/Funding Opportunity will be qualified for a higher level of funding.  
- Clinical trials not allowed. | - The maximum period of performance is 3 years.  
- The maximum allowable funding for the entire period of performance is $450,000 in direct costs ($600,000 in direct costs if requesting an Optional Qualified Collaborator).  
- Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 18, 2011  
5:00 p.m. Eastern time (ET)  
Application:  
August 1, 2011  
11:59 p.m. ET |